Onclive Team

Platinum-taxane combination therapy remains the standard for treatment of advanced cervical cancer, according to results of a randomized trial.

An investigational prostate cancer vaccine has shown potential to improve survival in patients with metastatic castration-resistant prostate cancer (CRPC).

Investigators identified three proteins that were able to predict response to treatment with a MEK inhibitor plus a PI3 kinase inhibitor-an investigational approach to NSCLC, including some KRAS-mutated cancers.

A dual-action PARP inhibitor has shown sufficient clinical activity to continue its investigation in women with recurrent BRCA-mutant ovarian cancer.

Prostate cancer prognosis remains poor for patients who have a prostate-specific antigen level ≥100 ng/mL at discovery, a review of cancer registry data showed.

Squamous cell carcinomas of the head and neck have different patterns of genetic alterations, some of which may be actionable or druggable with available agents or drugs in development.

Using an intermittent dosing strategy with vemurafenib, instead of continuous dosing, has the potential to overcome the development of resistance in patients with melanoma treated with the drug.

In an interview with OncologyLive, Brian G.M. Durie, MD, provided details about the Black Swan initiative and how he expects the project to develop.

Progression-free survival doubled in men with metastatic castration-resistant prostate cancer with no chemotherapy exposure who were treated with abiraterone acetate plus prednisone versus prednisone alone.

Women with the highest expression of HER2 had the most benefit from T-DM1, while the presence of PIK3CA mutations had no effect on response to T-DM1 but did interfere with response to capecitabine/lapatinib.

Ibrutinib was well tolerated and highly effective in eradicating tumor cells in both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia in an ongoing phase II study.

Discussions about new guidelines on molecular testing in patients with lung cancer and a keynote address from prominent researcher Tony S. Mok, MD, will be among the highlights of the upcoming 14th International Lung Cancer Congress.

Clinical pathway programs are evolving as a primary means by which payers intend to control drug utilization in cancer treatment.

Mutations of the HER2 gene in patients with non-small cell lung cancer, though rare, potentially could be treated with HER2-targeted drugs.

At the 18th Annual Conference of the National Comprehensive Cancer Network, experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.

Breast cancer clinicians today are faced with an ever-expanding number of older patients, yet determining the most appropriate treatment for these individuals can be challenging.

The FDA concurrently approved erlotinib along with a companion diagnostic to be used together in the first-line treatment of patients with metastatic non-small cell lung cancer harboring a specific EGFR mutation.

Despite progress in treating chemotherapy-induced nausea and vomiting, especially in the acute phase up to 24 hours after treatment, the condition is still one of the side effects patients fear most.

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program. This program enables the Herbert Irving Comprehensive Cancer Center to promote its institution and faculty as leaders in oncology to a national audience of oncology professionals.

An estimated 16,000 urologists will be needed to provide specialty care by 2025, but estimates of the number of urologists likely to be in practice at that time range between 6800 and 7400.

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

The 108th AUA Annual Meeting held May 4-8 in San Diego, California, contained over 2,000 presentations focused on urologic medicine. This entry contains summaries of four abstracts focused on urothelial, testicular, and prostate cancer.

Expectant management, which includes active surveillance and watchful waiting, is widely underused in the treatment of prostate cancer in the United States.

Photos from the Oncology Nursing Society 38th Annual Congress, held at the Walter E. Washington Convention Center in Washington, D.C, from April 15-28, 2013.

Interview With Andrew Pecora, MD, President, Regional Cancer Care Associates, Chief Innovations Officer and Vice President, Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, Editor-in-Chief, Oncology & Biotech News

The Biotech Focus series provides updates on advances in the oncology treatment pipeline. In each entry, summaries of ongoing research, breaking news, and FDA decisions relating to a variety of cancers are presented.

The Trials in Progress series is intended to stimulate discussion about ongoing clinical trials, to promote collaboration across the oncology community.

J. Michael Dixon, MD, describes a number of effective options for clinicians to help patients better manage menopausal symptoms in patients with breast cancer and improve their quality of life.

The 108th American Urological Association (AUA) Annual Meeting is being held at the San Diego Convention Center from May 4 - 8, 2013, and features research, guideline updates, and the latest advances in urologic medicine.